Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $6.84 million.

Financial Guidance for 2024 Reiterated (initial guidance provided on March 13, 2024)

On a GAAP basis, we continue to expect total operating expenses in the range of approximately $145 million to $165 million in 2024, which includes non-cash stock-based compensation expense and depreciation and amortization, subject to additional funding.
We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, and depreciation and amortization of approximately $7 million, in the range of approximately $125 million to $145 million in 2024, subject to additional funding.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.